There are currently 129 active clinical trials seeking participants for Multiple Sclerosis research studies. The states with the highest number of trials for Multiple Sclerosis participants are Florida, New York, California and Texas.
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
NCT06677710
Recruiting
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/19/2025
Locations: Stanford University, Stanford, California +4 locations
Conditions: Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
Register for Updates
Feasibility of Remote Exercise Training for Hispanics/Latinos With MS
NCT05998616
Recruiting
The goal of this clinical trial is to investigate the potential benefits of a specially designed exercise program for Hispanics/Latinos with multiple sclerosis (MS). The main questions it aims to answer are: * Can a 4-month remotely-delivered exercise training program improve physical function, symptom management, and quality of life in Hispanics/Latinos with MS? * How do social determinants of health, such as income, education, access to healthcare, and social support, influence the feasibilit... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/18/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Multiple Sclerosis
Register for Updates
Kesimpta (Ofatumumab) Pregnancy Registry
NCT05634967
Recruiting
The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/12/2025
Locations: University of California San Diego OTIS, La Jolla, California
Conditions: Multiple Sclerosis, Pregnancy
Register for Updates
HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) - Multiple Sclerosis (MS)
NCT06145737
Recruiting
The goal of this pilot study is to assess the feasibility of adapting and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with multiple sclerosis (MS). The main questions it aims to answer are: 1. Can the current HOBSCOTCH program be adapted for people with MS? 2. Will people with MS experience improved quality of life similar to that found in people with epilepsy after participating in the HOBSCOTCH program? Participants will be asked to: * at... Read More
Gender:
ALL
Ages:
Between 20 years and 65 years
Trial Updated:
01/07/2025
Locations: Dartmouth-Hitchcock, Lebanon, New Hampshire
Conditions: Multiple Sclerosis, Cognitive Dysfunction, Memory Disorders
Register for Updates
Entire-body PET Scans for Multiple Sclerosis
NCT04390009
Recruiting
To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.
Gender:
ALL
Ages:
Between 25 years and 55 years
Trial Updated:
01/04/2025
Locations: Brain Health Alliance, Ladera Ranch, California
Conditions: Multiple Sclerosis
Register for Updates
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
NCT02994121
Recruiting
In this longitudinal prospective natural history study of multiple sclerosis (MS), the overarching goal is to understand the factors that influence individual variation in disease trajectory and treatment response and pave the way for realizing precision medicine in MS. Because MS is a chronic neurological disorder, this observational cohort study will span a 30-year time frame.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
01/01/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Multiple Sclerosis
Register for Updates
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
NCT06136728
Recruiting
The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine? * Is the combined treatment associated with better outcomes than the medication (dalfa... Read More
Gender:
ALL
Ages:
Between 25 years and 75 years
Trial Updated:
12/16/2024
Locations: MGH Institute of Health Professions, Boston, Massachusetts
Conditions: Multiple Sclerosis
Register for Updates
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
NCT03759522
Recruiting
The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET radiopharmaceutical \[F-18\]DPA-714 in individuals with chronic pain and fatigue suspected to be associated with neuroinflammation. The PET tracer \[F-18\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-in... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/13/2024
Locations: University of Alabama at Birmingham Medical Center, Birmingham, Alabama
Conditions: Fibromyalgia, Chronic Fatigue Syndrome, Multiple Sclerosis, Healthy
Register for Updates
Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS
NCT05500963
Recruiting
The objective of the randomized, sham-controlled trial will be to evaluate the effectiveness of treatment with transcutaneous electrical nerve stimulation (TENS) at reducing the level of fatigue experienced by people with MS.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/05/2024
Locations: University of Colorado, Boulder, Colorado
Conditions: Multiple Sclerosis
Register for Updates
MS-DETECT: Early Detection of Multiple Sclerosis Progression with MSCopilot® Detect
NCT05816122
Recruiting
The study aims to evaluate MSCopilot® Detect, a smartphone application for at-home monitoring of patients with Multiple Sclerosis (MS). The primary objective is to enhance and standardize remote monitoring of MS patients to accurately assess disease progression caused by either Relapse Activity Worsening (RAW) or Progression Independent of Relapses (PIRA). The study also aims to assess the safety, usability, and satisfaction of the solution. A secondary objective is to determine MSCopilot® Det... Read More
Gender:
ALL
Ages:
Between 30 years and 65 years
Trial Updated:
12/04/2024
Locations: Jennifer Graves, San Diego, California +35 locations
Conditions: Multiple Sclerosis
Register for Updates
Obesity and Pediatric Multiple Sclerosis
NCT04593082
Recruiting
Obesity is one possible contributor to severity of multiple sclerosis and progression of the disease. We already know that obesity is a risk determinant for acquiring MS, yet the impact of obesity on pediatric MS disease expression and course is unknown. This study will evaluate the relationship between obesity, obesity-derived inflammatory mediators, and imaging metrics of MS severity in children. Understanding how childhood obesity contributes to MS severity/progression may yield fundamental i... Read More
Gender:
ALL
Ages:
Between 10 years and 20 years
Trial Updated:
12/03/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania +1 locations
Conditions: Multiple Sclerosis
Register for Updates
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
NCT05285891
Recruiting
This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, and 24. At Month 24, participants will be randomized (2:1) to one of two Arms with randomized treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/03/2024
Locations: Yale School of Medicine, New Haven, Connecticut +10 locations
Conditions: Multiple Sclerosis
Register for Updates